SCHEMBL6479943

SCHEMBL6479943

COC(=O)[C@@H]1CS[C@H]2C[C@@](Cc3ccccc3)(NC(=O)OC(C)(C)C)C(=O)N21

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PPIA P62937 1/20 0.40
KLK5 Q9Y337 1/20 0.38
DPP4 P27487 2/20 0.38
AGTR2 P50052 2/20 0.36
GRIN2B Q13224 1/20 0.36
KMT2A Q03164 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA7 P43166 1/20 0.35
CA14 Q9ULX7 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C19 P33261 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
FKBP1A P62942 1/20 0.34
GFER P55789 1/20 0.33
MMP2 P08253 1/20 0.33
AKT1 P31749 1/20 0.33
ATM Q13315 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1728442 0.93 PPIA (0.39) PPIADPP4AGTR2GRIN2BKMT2A
SCHEMBL1730102 0.92 DPP4 (0.40) PPIADPP4AGTR2GRIN2BKMT2A
SCHEMBL1730373 0.85 PPIA (0.41) PPIADPP4AGTR2GRIN2BKMT2A
SCHEMBL8294822 0.85 PPIA (0.31) PPIA
SCHEMBL1728443 0.85 PPIA (0.40) PPIADPP4GRIN2BKMT2ACA12
SCHEMBL6479927 0.83 DPP4 (0.35) PPIADPP4AGTR2GFER
SCHEMBL6474079 0.83 DPP4 (0.35) PPIADPP4AGTR2GFER
SCHEMBL6063409 0.83 DPP4 (0.35) PPIADPP4AGTR2GFER
SCHEMBL13205166 0.82 CYP2C19 (0.37) PPIAKLK5DPP4KMT2ASMN1; SMN2
SCHEMBL2970547 0.82 CYP2C19 (0.37) PPIAKLK5DPP4KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059716-A1 Novel bicyclic cyanoheterocycles, process for their preparation and their use as medicaments AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059716-A1 Novel bicyclic cyanoheterocycles, process for their preparation and their use as medicaments CYP11B2, GOT2, CYP11B1 PPIA 934/4885KLK5 3738/4885DPP4 374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.